drugset / Trial / NCT00004376
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
Phase 3
Completed
35 enrolled
National Center for Research Resources (NCRR)
Yale University · collab
Treatment
Summary
OBJECTIVES: I. Evaluate the safety and efficacy of the alpha-2 adrenergic agonist guanfacine in children and adolescents with Tourette syndrome or other chronic tic disorder, and attention deficit hyperactivity disorder.
Timeline
- Start
- 1994-09
- Primary completion
- —
- Completion
- 2000-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guanfacine | Small molecule | — | Oral |